Clinical trial · Observational
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
NCT02389972CI-TRIAL-00029461completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dasatinib | Drug | Dasatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- CML patients treated with dasatinib
- description
- Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
- interventionNames
- Drug: Dasatinib
Primary outcomes (3)
- measure
- Rate of Hematologic response (HR) for Chronic phase (CP), Advanced phase (AP),Blast phase (BP)
- timeFrame
- Upto 2 years
- description
- Hematological Response is a normalization of the blood counts, particularly white blood cell counts. This is the first noticeable indicator that treatment is beginning to work, though not necessarily in the bone marrow
- measure
- Rate of Cytogenetic response (CR) for Chronic phase, Advanced phase,Blast phase
- timeFrame
- Upto 2 years
- description
- Cytogenetic Response is a response to treatment of CML that occurs in the marrow, rather than just in the blood
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Because this is a product registry study, it will include adult CML patients in any phase treated with dasatinib in China if they meet the following criteria: * Willing and able to provide written informed consent * ≥18 years of age * Confirmed diagnosis of CML patients by attending physician * Naive to dasatinib before enrollment in study treatment or have received \<3 months of dasatinib treatment * Plan to or are receiving dasatinib therapy based on physician's clinical judgment * Administered dasatinib after imatinib-resistance or intolerance Exclusion Criteria: \- Patients participating in clinical trials for CML that explicitly prohibit recruitment in additional studies
References
Publications (0)
Data not yet available
No reference posted for this study.